- Mylan N.V. (MYL -0.3%) is under modest pressure on below-average volume in early trade in apparent response to a rumored SEC lawsuit over its lack of disclosure related to its Medicaid pricing of EpiPen.
- Shares have sold off over 13% since peaking at ~$22.50 several weeks ago.
- Update: In a statement, the SEC says the company has agreed to $30M to settle its charges that it paid Medicaid lower rebates on EpiPen sales by classifying the branded product as generic.